Kaposi’s Sarcoma: Evaluation of Clinical Features, Treatment Outcomes, and Prognosis in a Single-Center Retrospective Case Series
Kaposi’s sarcoma (KS) is a rare angioproliferative tumor classified in four different clinical–epidemiological forms. The diagnosis is based on histopathological and immunohistochemical analyses. The treatment is heterogeneous and includes several local and systemic therapeutic strategies. Methods:...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/16/4/691 |
| _version_ | 1797298669313064960 |
|---|---|
| author | Irene Russo Dario Marino Claudia Cozzolino Paolo Del Fiore Fitnete Nerjaku Silvia Finotto Annamaria Cattelan Maria Luisa Calabrò Anna Belloni Fortina Francesco Russano Marcodomenico Mazza Sara Galuppo Elisabetta Bezzon Marta Sbaraglia Marco Krengli Antonella Brunello Simone Mocellin Stefano Piaserico Mauro Alaibac |
| author_facet | Irene Russo Dario Marino Claudia Cozzolino Paolo Del Fiore Fitnete Nerjaku Silvia Finotto Annamaria Cattelan Maria Luisa Calabrò Anna Belloni Fortina Francesco Russano Marcodomenico Mazza Sara Galuppo Elisabetta Bezzon Marta Sbaraglia Marco Krengli Antonella Brunello Simone Mocellin Stefano Piaserico Mauro Alaibac |
| author_sort | Irene Russo |
| collection | DOAJ |
| description | Kaposi’s sarcoma (KS) is a rare angioproliferative tumor classified in four different clinical–epidemiological forms. The diagnosis is based on histopathological and immunohistochemical analyses. The treatment is heterogeneous and includes several local and systemic therapeutic strategies. Methods: This is a retrospective cohort study including 86 KS patients treated between 1993 and 2022 at the University Hospital of Padua (AOPD) and at the Veneto Institute of Oncology (IOV). The data were extracted from an electronic database. Survival curves were generated using the Kaplan–Meier method, and Cox regression models were employed to explore associations with overall and disease-free survival. The male sex (89.53%), classical variant (43.02%), and cutaneous involvement (77.9%) were predominant. More than 61.6% of patients received a single treatment. Surgery, antiretroviral therapy, and chemotherapy were the mostly adopted approaches. A persistent response was observed in approximately 65% of patients, with a 22% relapse rate (at least 2 years). The overall survival ranges from 90 to 70% at 2 to 10 years after the diagnosis. Iatrogenic KS demonstrated a higher mortality (52.9%). This study reflects our experience in the management of KS. Comorbidities are very frequent, and treatments are heterogeneous. A multidisciplinary approach involving multiple referral specialists is essential for the appropriate management of this disease during diagnosis, treatment, and follow-up. |
| first_indexed | 2024-03-07T22:38:22Z |
| format | Article |
| id | doaj.art-126cf0072f864005a47d194c8b5ac263 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-07T22:38:22Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-126cf0072f864005a47d194c8b5ac2632024-02-23T15:10:37ZengMDPI AGCancers2072-66942024-02-0116469110.3390/cancers16040691Kaposi’s Sarcoma: Evaluation of Clinical Features, Treatment Outcomes, and Prognosis in a Single-Center Retrospective Case SeriesIrene Russo0Dario Marino1Claudia Cozzolino2Paolo Del Fiore3Fitnete Nerjaku4Silvia Finotto5Annamaria Cattelan6Maria Luisa Calabrò7Anna Belloni Fortina8Francesco Russano9Marcodomenico Mazza10Sara Galuppo11Elisabetta Bezzon12Marta Sbaraglia13Marco Krengli14Antonella Brunello15Simone Mocellin16Stefano Piaserico17Mauro Alaibac18Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV – IRCCS, 35128 Padova, ItalyOncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV – IRCCS, 35128 Padova, ItalySoft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV – IRCCS, 35128 Padova, ItalySoft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV – IRCCS, 35128 Padova, ItalyDepartment of Medicine (DIMED), School of Medicine, University of Padova, 35128 Padova, ItalyOncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV – IRCCS, 35128 Padova, ItalyInfectious and Tropical Diseases Unit, Padova University Hospital, 35128 Padova, ItalyImmunology and Molecular Oncology, Veneto Institute of Oncology IOV – IRCCS, 35128 Padova, ItalyDermatology Unit, Department of Medicine, University of Padova, 35128 Padova, ItalySoft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV – IRCCS, 35128 Padova, ItalySoft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV – IRCCS, 35128 Padova, ItalyRadiotherapy Unit, Veneto Institute of Oncology IOV – IRCCS, 35128 Padova, ItalyRadiology Unit, Veneto Institute of Oncology, IOV – IRCCS, 35128 Padova, ItalyDepartment of Medicine (DIMED), School of Medicine, University of Padova, 35128 Padova, ItalyRadiotherapy Unit, Veneto Institute of Oncology IOV – IRCCS, 35128 Padova, ItalyOncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV – IRCCS, 35128 Padova, ItalySoft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV – IRCCS, 35128 Padova, ItalyDermatology Unit, Department of Medicine, University of Padova, 35128 Padova, ItalyDermatology Unit, Department of Medicine, University of Padova, 35128 Padova, ItalyKaposi’s sarcoma (KS) is a rare angioproliferative tumor classified in four different clinical–epidemiological forms. The diagnosis is based on histopathological and immunohistochemical analyses. The treatment is heterogeneous and includes several local and systemic therapeutic strategies. Methods: This is a retrospective cohort study including 86 KS patients treated between 1993 and 2022 at the University Hospital of Padua (AOPD) and at the Veneto Institute of Oncology (IOV). The data were extracted from an electronic database. Survival curves were generated using the Kaplan–Meier method, and Cox regression models were employed to explore associations with overall and disease-free survival. The male sex (89.53%), classical variant (43.02%), and cutaneous involvement (77.9%) were predominant. More than 61.6% of patients received a single treatment. Surgery, antiretroviral therapy, and chemotherapy were the mostly adopted approaches. A persistent response was observed in approximately 65% of patients, with a 22% relapse rate (at least 2 years). The overall survival ranges from 90 to 70% at 2 to 10 years after the diagnosis. Iatrogenic KS demonstrated a higher mortality (52.9%). This study reflects our experience in the management of KS. Comorbidities are very frequent, and treatments are heterogeneous. A multidisciplinary approach involving multiple referral specialists is essential for the appropriate management of this disease during diagnosis, treatment, and follow-up.https://www.mdpi.com/2072-6694/16/4/691Kaposi’s sarcomavascular sarcomaiatrogenic diseaseHIV-related diseaseimmunosuppression status |
| spellingShingle | Irene Russo Dario Marino Claudia Cozzolino Paolo Del Fiore Fitnete Nerjaku Silvia Finotto Annamaria Cattelan Maria Luisa Calabrò Anna Belloni Fortina Francesco Russano Marcodomenico Mazza Sara Galuppo Elisabetta Bezzon Marta Sbaraglia Marco Krengli Antonella Brunello Simone Mocellin Stefano Piaserico Mauro Alaibac Kaposi’s Sarcoma: Evaluation of Clinical Features, Treatment Outcomes, and Prognosis in a Single-Center Retrospective Case Series Cancers Kaposi’s sarcoma vascular sarcoma iatrogenic disease HIV-related disease immunosuppression status |
| title | Kaposi’s Sarcoma: Evaluation of Clinical Features, Treatment Outcomes, and Prognosis in a Single-Center Retrospective Case Series |
| title_full | Kaposi’s Sarcoma: Evaluation of Clinical Features, Treatment Outcomes, and Prognosis in a Single-Center Retrospective Case Series |
| title_fullStr | Kaposi’s Sarcoma: Evaluation of Clinical Features, Treatment Outcomes, and Prognosis in a Single-Center Retrospective Case Series |
| title_full_unstemmed | Kaposi’s Sarcoma: Evaluation of Clinical Features, Treatment Outcomes, and Prognosis in a Single-Center Retrospective Case Series |
| title_short | Kaposi’s Sarcoma: Evaluation of Clinical Features, Treatment Outcomes, and Prognosis in a Single-Center Retrospective Case Series |
| title_sort | kaposi s sarcoma evaluation of clinical features treatment outcomes and prognosis in a single center retrospective case series |
| topic | Kaposi’s sarcoma vascular sarcoma iatrogenic disease HIV-related disease immunosuppression status |
| url | https://www.mdpi.com/2072-6694/16/4/691 |
| work_keys_str_mv | AT irenerusso kaposissarcomaevaluationofclinicalfeaturestreatmentoutcomesandprognosisinasinglecenterretrospectivecaseseries AT dariomarino kaposissarcomaevaluationofclinicalfeaturestreatmentoutcomesandprognosisinasinglecenterretrospectivecaseseries AT claudiacozzolino kaposissarcomaevaluationofclinicalfeaturestreatmentoutcomesandprognosisinasinglecenterretrospectivecaseseries AT paolodelfiore kaposissarcomaevaluationofclinicalfeaturestreatmentoutcomesandprognosisinasinglecenterretrospectivecaseseries AT fitnetenerjaku kaposissarcomaevaluationofclinicalfeaturestreatmentoutcomesandprognosisinasinglecenterretrospectivecaseseries AT silviafinotto kaposissarcomaevaluationofclinicalfeaturestreatmentoutcomesandprognosisinasinglecenterretrospectivecaseseries AT annamariacattelan kaposissarcomaevaluationofclinicalfeaturestreatmentoutcomesandprognosisinasinglecenterretrospectivecaseseries AT marialuisacalabro kaposissarcomaevaluationofclinicalfeaturestreatmentoutcomesandprognosisinasinglecenterretrospectivecaseseries AT annabellonifortina kaposissarcomaevaluationofclinicalfeaturestreatmentoutcomesandprognosisinasinglecenterretrospectivecaseseries AT francescorussano kaposissarcomaevaluationofclinicalfeaturestreatmentoutcomesandprognosisinasinglecenterretrospectivecaseseries AT marcodomenicomazza kaposissarcomaevaluationofclinicalfeaturestreatmentoutcomesandprognosisinasinglecenterretrospectivecaseseries AT saragaluppo kaposissarcomaevaluationofclinicalfeaturestreatmentoutcomesandprognosisinasinglecenterretrospectivecaseseries AT elisabettabezzon kaposissarcomaevaluationofclinicalfeaturestreatmentoutcomesandprognosisinasinglecenterretrospectivecaseseries AT martasbaraglia kaposissarcomaevaluationofclinicalfeaturestreatmentoutcomesandprognosisinasinglecenterretrospectivecaseseries AT marcokrengli kaposissarcomaevaluationofclinicalfeaturestreatmentoutcomesandprognosisinasinglecenterretrospectivecaseseries AT antonellabrunello kaposissarcomaevaluationofclinicalfeaturestreatmentoutcomesandprognosisinasinglecenterretrospectivecaseseries AT simonemocellin kaposissarcomaevaluationofclinicalfeaturestreatmentoutcomesandprognosisinasinglecenterretrospectivecaseseries AT stefanopiaserico kaposissarcomaevaluationofclinicalfeaturestreatmentoutcomesandprognosisinasinglecenterretrospectivecaseseries AT mauroalaibac kaposissarcomaevaluationofclinicalfeaturestreatmentoutcomesandprognosisinasinglecenterretrospectivecaseseries |